Literature DB >> 15623758

Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community.

Emily S West1, Beatriz Munoz, Harran Mkocha, Martin J Holland, Aura Aguirre, Anthony W Solomon, Robin Bailey, Allen Foster, David Mabey, Sheila K West.   

Abstract

PURPOSE: Trachoma remains a leading cause of blindness. Determining the most effective antibiotic treatment strategy is essential for the success of country-based trachoma control programs.
METHODS: Baseline and 2-month follow-up examinations were performed in a trachoma-hyperendemic village. All residents were offered azithromycin for trachoma after baseline was determined. Infection with Chlamydia trachomatis and chlamydial load were determined by PCR. Clinical trachoma status was evaluated. A high chlamydial load was defined as a higher than median chlamydial load among those with infection. Risk factors were examined in multiple logistic regression models. Associations are presented as odds ratios and 95% confidence intervals.
RESULTS: At baseline, 57% of participants were infected with C. trachomatis. Although clinical trachoma correlated with infection, 23% of participants with high chlamydial loads showed no clinical signs. Adults represented only 10% of the population with high loads. Treatment significantly decreased the proportion positive in the community and the load in the community. However, 27% of individuals with high loads at baseline who received treatment also were infected at 2 months. Of those, 93% with high loads at 2 months were aged < or =10 years.
CONCLUSIONS: Although most of the chlamydial load in this community resided in children, 10% of the high load resided in adults, most of whom did not have follicular trachoma and in whom the infection would be missed under treatment strategies that focus on clinical disease or children. These data support a mass treatment strategy for hyperendemic communities, at least as a first approach. In addition, treatment of children age < or =2 years should be reexamined, as >30% with high loads at baseline remained infected at 2 months, despite monitored treatment according to weight.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15623758      PMCID: PMC6853789          DOI: 10.1167/iovs.04-0327

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  13 in total

Review 1.  WHO alliance for the global elimination of blinding trachoma and the potential use of azithromycin.

Authors:  A D Négrel; S P Mariotti
Journal:  Int J Antimicrob Agents       Date:  1998-11       Impact factor: 5.283

2.  Diagnosis of Chlamydia trachomatis eye infection in Tanzania by polymerase chain reaction/enzyme immunoassay.

Authors:  L Bobo; B Munoz; R Viscidi; T Quinn; H Mkocha; S West
Journal:  Lancet       Date:  1991-10-05       Impact factor: 79.321

3.  Conjunctival scarring in trachoma is associated with depressed cell-mediated immune responses to chlamydial antigens.

Authors:  M J Holland; R L Bailey; L J Hayes; H C Whittle; D C Mabey
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226

4.  Incidence of trichiasis in a cohort of women with and without scarring.

Authors:  B Muñoz; L Bobo; H Mkocha; M Lynch; Y H Hsieh; S West
Journal:  Int J Epidemiol       Date:  1999-12       Impact factor: 7.196

5.  Azithromycin in control of trachoma.

Authors:  J Schachter; S K West; D Mabey; C R Dawson; L Bobo; R Bailey; S Vitale; T C Quinn; A Sheta; S Sallam; H Mkocha; D Mabey; H Faal
Journal:  Lancet       Date:  1999-08-21       Impact factor: 79.321

6.  Cost-effectiveness of trachoma control measures: comparing targeted household treatment and mass treatment of children.

Authors:  K D Frick; T M Lietman; S O Holm; H C Jha; J S Chaudhary; R C Bhatta
Journal:  Bull World Health Organ       Date:  2003-07-07       Impact factor: 9.408

7.  The epidemiology of trachoma in central Tanzania.

Authors:  S K West; B Munoz; V M Turner; B B Mmbaga; H R Taylor
Journal:  Int J Epidemiol       Date:  1991-12       Impact factor: 7.196

8.  Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments.

Authors:  Muluken Melese; Jaya Devi Chidambaram; Wondu Alemayehu; David Chung Lee; Elizabeth H Yi; Vicky Cevallos; Zhaoxia Zhou; Cathy Donnellan; Michael Saidel; John P Whitcher; Bruce D Gaynor; Thomas M Lietman
Journal:  JAMA       Date:  2004-08-11       Impact factor: 56.272

9.  Antibiotic dosage in trachoma control programs: height as a surrogate for weight in children.

Authors:  Beatriz Muñoz; Anthony W Solomon; James Zingeser; Rachel Barwick; Matthew Burton; Robin Bailey; David Mabey; Allen Foster; Sheila K West
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-04       Impact factor: 4.799

10.  Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in Gambian villages.

Authors:  Matthew J Burton; Martin J Holland; Nkoyo Faal; Esther A N Aryee; Neal D E Alexander; Momodou Bah; Hannah Faal; Sheila K West; Allen Foster; Gordon J Johnson; David C W Mabey; Robin L Bailey
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-10       Impact factor: 4.799

View more
  40 in total

1.  Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control.

Authors:  Sheila K West; Beatriz E Munoz; Harran Mkocha; Charlotte Gaydos; Thomas Quinn
Journal:  Ophthalmic Epidemiol       Date:  2015       Impact factor: 1.648

Review 2.  The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infection.

Authors:  P Horner
Journal:  Sex Transm Infect       Date:  2006-08       Impact factor: 3.519

3.  School-Based versus Community-Based Sampling for Trachoma Surveillance.

Authors:  Joseph P Sheehan; Sintayehu Gebresillasie; Ayalew Shiferaw; Solomon Aragie; Zerihun Tadesse; Demelash Tadesse; Thanapong Somkijrungroj; Nicole E Stoller; E Kelly Callahan; Paul M Emerson; Thomas M Lietman; Jeremy D Keenan
Journal:  Am J Trop Med Hyg       Date:  2018-05-24       Impact factor: 2.345

4.  Detection by broad-range real-time PCR assay of Chlamydia species infecting human and animals.

Authors:  P Goldschmidt; H Rostane; M Sow; A Goépogui; L Batellier; C Chaumeil
Journal:  Br J Ophthalmol       Date:  2006-08-09       Impact factor: 4.638

5.  Association of conjunctival bacterial infection and female sex in cicatricial trachoma.

Authors:  Vicky Cevallos; John P Whitcher; Muluken Melese; Wondu Alemayehu; Elizabeth Yi; Jaya D Chidambaram; Scott Lee; Harsha Reddy; Bruce D Gaynor; Thomas M Lietman; Jeremy D Keenan
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-08-07       Impact factor: 4.799

6.  Geospatial distribution and clustering of Chlamydia trachomatis in communities undergoing mass azithromycin treatment.

Authors:  Jithin Yohannan; Bing He; Jiangxia Wang; Gregory Greene; Yvette Schein; Harran Mkocha; Beatriz Munoz; Thomas C Quinn; Charlotte Gaydos; Sheila K West
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-06-06       Impact factor: 4.799

Review 7.  Ocular Chlamydia trachomatis infection: elimination with mass drug administration.

Authors:  Meraf A Wolle; Sheila K West
Journal:  Expert Rev Anti Infect Ther       Date:  2019-02-18       Impact factor: 5.091

8.  Do infants increase the risk of re-emergent infection in households after mass drug administration for trachoma?

Authors:  Sheila K West; Dianne Stare; Harran Mkocha; Beatriz Munoz; Charlotte Gaydos; Thomas C Quinn
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-29       Impact factor: 4.799

Review 9.  Strategies to control trachoma.

Authors:  Anu A Mathew; Angus Turner; Hugh R Taylor
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

10.  The development of an age-structured model for trachoma transmission dynamics, pathogenesis and control.

Authors:  Manoj Gambhir; Maria-Gloria Basáñez; Matthew J Burton; Anthony W Solomon; Robin L Bailey; Martin J Holland; Isobel M Blake; Christl A Donnelly; Ibrahim Jabr; David C Mabey; Nicholas C Grassly
Journal:  PLoS Negl Trop Dis       Date:  2009-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.